All resolutions concerning antiinfective medicinal products

Dolutegravir / Lamivudin Dovato® ViiV Healthcare GmbH Infectious diseases INFECT HIV infection 100% no additional benefit
Glecaprevir / Pibrentasvir (2) Maviret® AbbVie Deutschland GmbH & Co. KG Infectious diseases INFECT Chronic hepatitis C infection 100% no additional benefit
Doravirin Pifeltro® MSD Sharp & Dohme GmbH Infectious diseases INFECT HIV infection 100% no additional benefit
Doravirin / Lamivudin / Tenofovirdisoproxil Delstrigo® MSD Sharp & Dohme GmbH Infectious diseases INFECT HIV infection 100% no additional benefit
Bedaquilin Sirturo® Janssen-Cilag GmbH Infectious diseases INFECT ORPHAN Tuberculosis 100% Hint for considerable additional benefit
Tenofoviralafenamid (2, reassessment) Vemlidy® Gilead Sciences GmbH Infectious diseases INFECT Chronic hepatitis B infection 100% no additional benefit
Bictegravir / Emtricitabin / Tenofoviralafenamid Biktarvy® Gilead Sciences GmbH Infectious diseases INFECT HIV infection 100% no additional benefit
Dolutegravir / Rilpivirin Juluca® ViiV Healthcare GmbH Infectious diseases INFECT HIV infection 100% no additional benefit
Bezlotoxumab Zinplava® MSD Sharp & Dohme GmbH Infectious diseases INFECT Clostridium difficile associated diarrhea (CDAD) 100% Hint for minor additional benefit
Letermovir Prevymis® MSD Sharp & Dohme GmbH Infectious diseases INFECT ORPHAN Cytomegalovirus (CMV) prevention 100% non-quantifiable additional benefit
Elvitegravir / Cobicistat / Emtricitabin / Tenofoviralafenamid (2) Genvoya® Gilead Sciences GmbH Infectious diseases INFECT HIV infection 100% no additional benefit
Elvitegravir / Cobicistat / Emtricitabin / Tenofovirdisoproxil (2) Stribild® Gilead Sciences GmbH Infectious diseases INFECT HIV infection 100% no additional benefit
Sofosbuvir (2) Sovaldi® Gilead Sciences GmbH Infectious diseases INFECT Chronic hepatitis C infection 100% Indication for non-quantifiable additional benefit
Darunavir / Cobicistat / Emtricitabin / Tenofoviralafenamid Symtuza® Janssen-Cilag GmbH Infectious diseases INFECT HIV infection 100% no additional benefit
Sofosbuvir / Velpatasvir / Voxilaprevir Vosevi® Gilead Sciences GmbH Infectious diseases INFECT Chronic hepatitis C infection 100% no additional benefit
Ledipasvir / Sofosbuvir (2) Harvoni® Gilead Sciences GmbH Infectious diseases INFECT Chronic hepatitis C infection 50% Indication for non-quantifiable additional benefit
Glecaprevir / Pibrentasvir Maviret® AbbVie Deutschland GmbH & Co. KG Infectious diseases INFECT Chronic hepatitis C infection 100% no additional benefit
Tenofoviralafenamid Vemlidy® Gilead Sciences GmbH Infectious diseases INFECT Chronic hepatitis B infection 100% no additional benefit
Dolutegravir (2) Tivicay® ViiV Healthcare GmbH Infectious diseases INFECT HIV infection 100% no additional benefit
Elbasvir / Grazoprevir Zepatier® MSD Sharp & Dohme GmbH Infectious diseases INFECT Chronic hepatitis C infection 100% no additional benefit
Emtricitabin / Rilpivirin / Tenofoviralafenamid Odefsey® Gilead Sciences GmbH Infectious diseases INFECT HIV infection 100% no additional benefit
Sofosbuvir / Velpatasvir Epclusa® Gilead Sciences GmbH Infectious diseases INFECT Chronic hepatitis C infection 28% Indication for considerable additional benefit
Emtricitabin / Tenofoviralafenamid Descovy® Gilead Sciences GmbH Infectious diseases INFECT HIV infection 100% no additional benefit
Rilpivirin (2) Edurant® Janssen-Cilag GmbH Infectious diseases INFECT HIV infection 100% no additional benefit
Elvitegravir / Cobicistat / Emtricitabin / Tenofoviralafenamid Genvoya® Gilead Sciences GmbH Infectious diseases INFECT HIV infection 100% no additional benefit
Isavuconazol Cresemba® Basilea Pharmaceutica International Ltd. Infectious diseases INFECT ORPHAN Invasive aspergillosis and mucormycosis 100% non-quantifiable additional benefit
Ombitasvir / Paritaprevir / Ritonavir Viekirax® AbbVie Deutschland GmbH & Co. KG Infectious diseases INFECT Chronic hepatitis C infection 9% Hint for considerable additional benefit
Dasabuvir Exviera® AbbVie Deutschland GmbH & Co. KG Infectious diseases INFECT Chronic hepatitis C infection 24% Hint for considerable additional benefit
Ledipasvir / Sofosbuvir Harvoni® Gilead Sciences GmbH Infectious diseases INFECT Chronic hepatitis C infection 79% Indication for considerable additional benefit
Dolutegravir / Abacavir / Lamivudin Triumeq® ViiV Healthcare GmbH Infectious diseases INFECT HIV infection 9% Hint for considerable additional benefit
Daclatasvir Daklinza® Bristol-Myers Squibb GmbH & Co. KGaA Infectious diseases INFECT Chronic hepatitis C infection 1.4% Indication for considerable additional benefit
Simeprevir Olysio® Janssen-Cilag GmbH Infectious diseases INFECT Chronic hepatitis C infection, add-on treatment 91% Hint for considerable additional benefit
Cobicistat Tybost® Gilead Sciences GmbH Infectious diseases INFECT HIV infection, add-on treatment 100% no additional benefit
Sofosbuvir Sovaldi® Gilead Sciences GmbH Infectious diseases INFECT Chronic hepatitis C infection 4% Hint for considerable additional benefit
Dolutegravir Tivicay® ViiV Healthcare GmbH Infectious diseases INFECT HIV infection 11% Proof of considerable additional benefit
Emtricitabin / Rilpivirin / Tenofovirdisoproxil (2) Eviplera® Gilead Sciences GmbH Infectious diseases INFECT HIV infection 100% no additional benefit
Elvitegravir / Cobicistat / Emtricitabin / Tenofovirdisoproxil Stribild® Gilead Sciences GmbH Infectious diseases INFECT HIV infection 100% no additional benefit
Fidaxomicin Dificlir® Astellas Pharma GmbH Infectious diseases INFECT Clostriudium difficile associated diarrhea (CDAD) 41% Proof of considerable additional benefit
Emtricitabin / Rilpivirin / Tenofovirdisoproxil Eviplera® Gilead Sciences GmbH Infectious diseases INFECT HIV infection 100% Proof of minor additional benefit
Rilpivirin Edurant® Janssen-Cilag GmbH Infectious diseases INFECT HIV infection 100% Proof of minor additional benefit
Telaprevir Incivo® Janssen-Cilag GmbH Infectious diseases INFECT Chronic hepatitis C infection 100% Hint for non-quantifiable additional benefit
Boceprevir Victrelis® MSD Sharp & Dohme GmbH Infectious diseases INFECT Chronic hepatitis C infection 100% non-quantifiable additional benefit